Project

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Ongoing - recruitment active · 2024 until 2027

Scherrer Julia, Aeppli Stefanie, Quinter Janine